Results 131 to 140 of about 281,573 (395)

Biomarkers of leukemia risk: benzene as a model. [PDF]

, 1998
Although relatively rare, leukemias place a considerable financial burden on society and cause psychologic trauma to many families. Leukemia is the most common cancer in children.
Smith, MT, Zhang, L
core   +3 more sources

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Blood, 2019
Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic ...
P. Baliakas, S. Jeromin, M. Iskas, A. Puiggros, K. Plevová, K. Plevová, F. Nguyen‐Khac, Z. Davis, G. Rigolin, A. Visentin, A. Xochelli, J. Delgado, F. Baran-Marszak, E. Stalika, P. Abrisqueta, Kristina Ďurechová, G. Papaioannou, V. Eclache, M. Dimou, T. Iliakis, R. Collado, M. Doubek, M. Doubek, M. Calasanz, Neus Ruiz‐Xivillé, C. Moreno, M. Jarošová, M. Jarošová, A. Leeksma, P. Panayiotidis, H. Podgornik, F. Cymbalista, A. Anagnostopoulos, L. Trentin, N. Stavroyianni, F. Davi, P. Ghia, A. Kater, A. Cuneo, Š. Pospíšilová, Š. Pospíšilová, B. Espinet, A. Athanasiadou, D. Oscier, C. Haferlach, K. Stamatopoulos   +45 more
semanticscholar   +1 more source

Genetic Engineering Methods in Primary T Cells

Advanced Therapeutics, EarlyView.
Primary T cells can be engineered to confer them with novel therapeutic functions, allowing them to treat a variety of conditions. Genetic engineering can be either stable or transient, aiming to either express or inhibit a target gene. This review discusses the various genetic engineering tools available as well as their characteristics and ...
Anthony Youssef, Hui‐Shan Li
wiley   +1 more source

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]

, 2017
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara, Bertorelle, Roberta, Facco, Monica, Frezzato, Federica, Imbergamo, Silvia, Piazza, Francesco, Piva, Elisa, Pizzi, Marco, Riva, Marcello, Scomazzon, Edoardo, Semenzato, Gianpietro, Trentin, Livio, Visentin, Andrea   +12 more
core   +1 more source

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Blood, 2019
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment-effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled
A. Roberts, Shuo Ma, T. Kipps, S. Coutre, M. Davids, B. Eichhorst, M. Hallek, J. Byrd, K. Humphrey, Lang Zhou, B. Chyla, J. Nielsen, J. Potluri, S. Y. Kim, M. Verdugo, S. Stilgenbauer, W. Wierda, J. Seymour   +17 more
semanticscholar   +1 more source

Management of chronic lymphocytic leukemia

Haematologica, 2014
In the last decade, the management of chronic lymphocytic leukemia has undergone profound changes that have been driven by an improved understanding of the biology of the disease and the approval of several new drugs. Moreover, many novel drugs are currently under evaluation for rapid approval or have been approved by regulatory agencies, further ...
GHIA , PAOLO PROSPERO, Hallek M.
openaire   +5 more sources

Optogenetic‐Controlled iPSC‐Based Vaccines for Prophylactic and Therapeutic Tumor Suppression in Mice

Advanced Science, EarlyView.
This study develops an a red/far‐red light‐controlled iPSC‐based vaccines (RIVA) based on the chimeric photosensory protein FnBphP and its interaction partner LDB3 for cancer immunotherapy. The RIVA preserves the multiple intrinsic tumor antigens of iPSCs and enables optogenetic control of the expression of the immune adjuvant type I interferon β under
Longliang Qiao, Lingxue Niu, Zhihao Wang, Di Dai, Shasha Tang, Xiaoding Ma, Zhenqiang Deng, Guiling Yu, Yang Zhou, Tao Yan, Xingwan Liu, Deqiang Kong, Linfeng Hu, Xiang Li, Junwei Zhao, Fengfeng Cai, Meiyan Wang, Haifeng Ye   +17 more
wiley   +1 more source

SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course

Haematologica, 2016
I In the last decade, the B-cell receptor has emerged as a pivotal stimulus in the pathogenesis of chronic lymphocytic leukemia, and a very feasible therapeutic target in this disease.
Nili Dezorella, Ben-Zion Katz, Mika Shapiro, Aaron Polliack, Chava Perry, Yair Herishanu   +5 more
doaj   +1 more source

Multimodal Image Analysis of Chronic Leukemic Lymphoproliferative Disorders and the Hypothesis of »Single« and »Multiple« Programmed Stops in the Development of Typical and Atypical Forms of Leukemias and Lymphomas [PDF]

, 2010
The study consisted of morphometric analysis, assessment of the argyrophilic nucleolar organization region (AgNOR) characteristics, and image cytometry (ICM) in different tumor mass compartments: bone marrow (BM), peripheral blood (PB) and lymph nodes ...
Biljana Jelić Puškarić, Branimr Jakšić, Delfa Radić-Krišto, Ika Kardum-Skelin, Matko Kardum, Ozren Jakšić   +5 more
core   +2 more sources

Emodin Alleviates Sepsis‐Induced Multiorgan Damage by Inhibiting NETosis through Targeting Neutrophils BCL‐10

Advanced Science, EarlyView.
Emodin targets BCL‐10 to modulate the BCL‐10/MALT1 complex, thereby suppressing NF‐κB activation and significantly exerting multiorgan protective effects in sepsis. Abstract Sepsis is a life‐threatening condition caused by dysregulated host responses to infection, characterized by excessive inflammation and abnormal coagulation.
Xiaolong Xu, Yumeng Yan, Meiling Zheng, Mina Zhang, Tengfei Chen, Zhicheng Qu, Yinglu Bai, Shuwen Zhang, Chunming Zhao, Yifan Shi, Yan Lin, Ning Wang, Yunjing Bai, Yating Zhai, Zhaofang Bai, Wei Guo, Qingquan Liu   +16 more
wiley   +1 more source